http://142-54-23-223.fusionmedialtd.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 13 Jul 2026 08:00:58 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://142-54-23-223.fusionmedialtd.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Lineage+Cell+Therapeutics+updates+COR1+corneal+cell+therapy+program/26760091.html <p>Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX) provided an update on its COR1 program, an allogeneic corneal endothelial cell (CEnC) transplant therapy in preclinical development for corneal endothelial disease.</p><p>The company said it has manufactured corneal endothelial cells using its AlloSCOPE platform that meet internal thresholds for potency, identity, and scale. Lineage said it will advance COR1 into in-vivo animal testing, with initial data expected later this year.</p><p>COR1 uses a "thaw-and-inject" formulation designed to allow cryopreserved storage and immediate use. The program employs the company's AlloSCOPE 5D manufacturing process, which uses bioreactor-based expansion and differentiation. Lineage said its two-tiered http://www.streetinsider.com/Corporate+News/Lineage+Cell+Therapeutics+updates+COR1+corneal+cell+therapy+program/26760091.html Mon, 13 Jul 2026 08:00:58 -0400 LCTX http://www.streetinsider.com/Press+Releases/Lineage+Provides+Update+on+COR1+Cell+Therapy+Program+for+Corneal+Endothelial+Disease/26760042.html <p class="bwalignc"> <b>Company Will Host Conference Call Today at 4:30 PM ET / 1:30 PM PT</b> </p><ul class="bwlistdisc"> <li> <b>COR1 Aims to Provide an “Off the Shelf” Supply of Allogeneic CEnCs for Patients Suffering from Corneal Endothelial Disease</b> </li> <li> <b>Utilizes the Company’s AlloSCOPE™ 5D Manufacturing Process, Featuring Seamless, Bioreactor-based Expansion and Differentiation</b> </li> <li> <b>Proprietary “Thaw and Inject (TAI)” Formulation Offers an Immediate-use Cryopreserved Product Profile to Facilitate Long-Term Storage</b> </li> <li> <b>Current Purity, Scale and Thaw-and-Inject Formulation Support a Superior Product Profile to Cadaver-Sourced Cells</b> </li> </ul> <p> CARLSBAD, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54568450&amp;newsitemid=20260713449564&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=509e3b06b1595c04db5374140f8a1d93" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, “off http://www.streetinsider.com/Press+Releases/Lineage+Provides+Update+on+COR1+Cell+Therapy+Program+for+Corneal+Endothelial+Disease/26760042.html Mon, 13 Jul 2026 08:00:00 -0400 A.36512754 A.40151759 LCTX LCTX O.00050368 O.01207978 O.02770996 http://www.streetinsider.com/Press+Releases/Lineage+Provides+Update+on+COR1+Cell+Therapy+Program+for+Corneal+Endothelial+Disease/26760042.html <p class="bwalignc"> <b>Company Will Host Conference Call Today at 4:30 PM ET / 1:30 PM PT</b> </p><ul class="bwlistdisc"> <li> <b>COR1 Aims to Provide an “Off the Shelf” Supply of Allogeneic CEnCs for Patients Suffering from Corneal Endothelial Disease</b> </li> <li> <b>Utilizes the Company’s AlloSCOPE™ 5D Manufacturing Process, Featuring Seamless, Bioreactor-based Expansion and Differentiation</b> </li> <li> <b>Proprietary “Thaw and Inject (TAI)” Formulation Offers an Immediate-use Cryopreserved Product Profile to Facilitate Long-Term Storage</b> </li> <li> <b>Current Purity, Scale and Thaw-and-Inject Formulation Support a Superior Product Profile to Cadaver-Sourced Cells</b> </li> </ul> <p> CARLSBAD, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54568450&amp;newsitemid=20260713449564&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=509e3b06b1595c04db5374140f8a1d93" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, “off http://www.streetinsider.com/Press+Releases/Lineage+Provides+Update+on+COR1+Cell+Therapy+Program+for+Corneal+Endothelial+Disease/26760042.html Mon, 13 Jul 2026 08:00:00 -0400 A.36512754 A.40151759 LCTX LCTX O.00050368 O.01207978 O.02770996 http://www.streetinsider.com/Press+Releases/Lineage+Provides+Update+on+COR1+Cell+Therapy+Program+for+Corneal+Endothelial+Disease/26760042.html <p class="bwalignc"> <b>Company Will Host Conference Call Today at 4:30 PM ET / 1:30 PM PT</b> </p><ul class="bwlistdisc"> <li> <b>COR1 Aims to Provide an “Off the Shelf” Supply of Allogeneic CEnCs for Patients Suffering from Corneal Endothelial Disease</b> </li> <li> <b>Utilizes the Company’s AlloSCOPE™ 5D Manufacturing Process, Featuring Seamless, Bioreactor-based Expansion and Differentiation</b> </li> <li> <b>Proprietary “Thaw and Inject (TAI)” Formulation Offers an Immediate-use Cryopreserved Product Profile to Facilitate Long-Term Storage</b> </li> <li> <b>Current Purity, Scale and Thaw-and-Inject Formulation Support a Superior Product Profile to Cadaver-Sourced Cells</b> </li> </ul> <p> CARLSBAD, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54568450&amp;newsitemid=20260713449564&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=509e3b06b1595c04db5374140f8a1d93" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, “off http://www.streetinsider.com/Press+Releases/Lineage+Provides+Update+on+COR1+Cell+Therapy+Program+for+Corneal+Endothelial+Disease/26760042.html Mon, 13 Jul 2026 08:00:00 -0400 A.36512754 A.40151759 LCTX LCTX O.00050368 O.01207978 O.02770996 http://www.streetinsider.com/Press+Releases/Lineage+Provides+Update+on+COR1+Cell+Therapy+Program+for+Corneal+Endothelial+Disease/26760042.html <p class="bwalignc"> <b>Company Will Host Conference Call Today at 4:30 PM ET / 1:30 PM PT</b> </p><ul class="bwlistdisc"> <li> <b>COR1 Aims to Provide an “Off the Shelf” Supply of Allogeneic CEnCs for Patients Suffering from Corneal Endothelial Disease</b> </li> <li> <b>Utilizes the Company’s AlloSCOPE™ 5D Manufacturing Process, Featuring Seamless, Bioreactor-based Expansion and Differentiation</b> </li> <li> <b>Proprietary “Thaw and Inject (TAI)” Formulation Offers an Immediate-use Cryopreserved Product Profile to Facilitate Long-Term Storage</b> </li> <li> <b>Current Purity, Scale and Thaw-and-Inject Formulation Support a Superior Product Profile to Cadaver-Sourced Cells</b> </li> </ul> <p> CARLSBAD, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54568450&amp;newsitemid=20260713449564&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=509e3b06b1595c04db5374140f8a1d93" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, “off http://www.streetinsider.com/Press+Releases/Lineage+Provides+Update+on+COR1+Cell+Therapy+Program+for+Corneal+Endothelial+Disease/26760042.html Mon, 13 Jul 2026 08:00:00 -0400 A.36512754 A.40151759 LCTX LCTX O.00050368 O.01207978 O.02770996 http://www.streetinsider.com/Press+Releases/Lineage+Provides+Update+on+COR1+Cell+Therapy+Program+for+Corneal+Endothelial+Disease/26760042.html <p class="bwalignc"> <b>Company Will Host Conference Call Today at 4:30 PM ET / 1:30 PM PT</b> </p><ul class="bwlistdisc"> <li> <b>COR1 Aims to Provide an “Off the Shelf” Supply of Allogeneic CEnCs for Patients Suffering from Corneal Endothelial Disease</b> </li> <li> <b>Utilizes the Company’s AlloSCOPE™ 5D Manufacturing Process, Featuring Seamless, Bioreactor-based Expansion and Differentiation</b> </li> <li> <b>Proprietary “Thaw and Inject (TAI)” Formulation Offers an Immediate-use Cryopreserved Product Profile to Facilitate Long-Term Storage</b> </li> <li> <b>Current Purity, Scale and Thaw-and-Inject Formulation Support a Superior Product Profile to Cadaver-Sourced Cells</b> </li> </ul> <p> CARLSBAD, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54568450&amp;newsitemid=20260713449564&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=509e3b06b1595c04db5374140f8a1d93" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, “off http://www.streetinsider.com/Press+Releases/Lineage+Provides+Update+on+COR1+Cell+Therapy+Program+for+Corneal+Endothelial+Disease/26760042.html Mon, 13 Jul 2026 08:00:00 -0400 A.36512754 A.40151759 LCTX LCTX O.00050368 O.01207978 O.02770996 http://www.streetinsider.com/Press+Releases/Lineage+Provides+Update+on+COR1+Cell+Therapy+Program+for+Corneal+Endothelial+Disease/26760042.html <p class="bwalignc"> <b>Company Will Host Conference Call Today at 4:30 PM ET / 1:30 PM PT</b> </p><ul class="bwlistdisc"> <li> <b>COR1 Aims to Provide an “Off the Shelf” Supply of Allogeneic CEnCs for Patients Suffering from Corneal Endothelial Disease</b> </li> <li> <b>Utilizes the Company’s AlloSCOPE™ 5D Manufacturing Process, Featuring Seamless, Bioreactor-based Expansion and Differentiation</b> </li> <li> <b>Proprietary “Thaw and Inject (TAI)” Formulation Offers an Immediate-use Cryopreserved Product Profile to Facilitate Long-Term Storage</b> </li> <li> <b>Current Purity, Scale and Thaw-and-Inject Formulation Support a Superior Product Profile to Cadaver-Sourced Cells</b> </li> </ul> <p> CARLSBAD, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54568450&amp;newsitemid=20260713449564&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=509e3b06b1595c04db5374140f8a1d93" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, “off http://www.streetinsider.com/Press+Releases/Lineage+Provides+Update+on+COR1+Cell+Therapy+Program+for+Corneal+Endothelial+Disease/26760042.html Mon, 13 Jul 2026 08:00:00 -0400 A.36512754 A.40151759 LCTX LCTX O.00050368 O.01207978 O.02770996 http://www.streetinsider.com/Press+Releases/Lineage+Provides+Update+on+COR1+Cell+Therapy+Program+for+Corneal+Endothelial+Disease/26760042.html <p class="bwalignc"> <b>Company Will Host Conference Call Today at 4:30 PM ET / 1:30 PM PT</b> </p><ul class="bwlistdisc"> <li> <b>COR1 Aims to Provide an “Off the Shelf” Supply of Allogeneic CEnCs for Patients Suffering from Corneal Endothelial Disease</b> </li> <li> <b>Utilizes the Company’s AlloSCOPE™ 5D Manufacturing Process, Featuring Seamless, Bioreactor-based Expansion and Differentiation</b> </li> <li> <b>Proprietary “Thaw and Inject (TAI)” Formulation Offers an Immediate-use Cryopreserved Product Profile to Facilitate Long-Term Storage</b> </li> <li> <b>Current Purity, Scale and Thaw-and-Inject Formulation Support a Superior Product Profile to Cadaver-Sourced Cells</b> </li> </ul> <p> CARLSBAD, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54568450&amp;newsitemid=20260713449564&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=509e3b06b1595c04db5374140f8a1d93" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, “off http://www.streetinsider.com/Press+Releases/Lineage+Provides+Update+on+COR1+Cell+Therapy+Program+for+Corneal+Endothelial+Disease/26760042.html Mon, 13 Jul 2026 08:00:00 -0400 A.36512754 A.40151759 LCTX LCTX O.00050368 O.01207978 O.02770996 http://www.streetinsider.com/Business+Wire/Lineage+Provides+Update+on+COR1+Cell+Therapy+Program+for+Corneal+Endothelial+Disease/26760042.html <p class="bwalignc"> <b>Company Will Host Conference Call Today at 4:30 PM ET / 1:30 PM PT</b> </p><ul class="bwlistdisc"> <li> <b>COR1 Aims to Provide an “Off the Shelf” Supply of Allogeneic CEnCs for Patients Suffering from Corneal Endothelial Disease</b> </li> <li> <b>Utilizes the Company’s AlloSCOPE™ 5D Manufacturing Process, Featuring Seamless, Bioreactor-based Expansion and Differentiation</b> </li> <li> <b>Proprietary “Thaw and Inject (TAI)” Formulation Offers an Immediate-use Cryopreserved Product Profile to Facilitate Long-Term Storage</b> </li> <li> <b>Current Purity, Scale and Thaw-and-Inject Formulation Support a Superior Product Profile to Cadaver-Sourced Cells</b> </li> </ul> <p> CARLSBAD, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54568450&amp;newsitemid=20260713449564&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=509e3b06b1595c04db5374140f8a1d93" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, “off http://www.streetinsider.com/Business+Wire/Lineage+Provides+Update+on+COR1+Cell+Therapy+Program+for+Corneal+Endothelial+Disease/26760042.html Mon, 13 Jul 2026 08:00:00 -0400 A.36512754 A.40151759 LCTX LCTX O.00050368 O.01207978 O.02770996 http://www.streetinsider.com/Business+Wire/Lineage+Provides+Update+on+COR1+Cell+Therapy+Program+for+Corneal+Endothelial+Disease/26760042.html <p class="bwalignc"> <b>Company Will Host Conference Call Today at 4:30 PM ET / 1:30 PM PT</b> </p><ul class="bwlistdisc"> <li> <b>COR1 Aims to Provide an “Off the Shelf” Supply of Allogeneic CEnCs for Patients Suffering from Corneal Endothelial Disease</b> </li> <li> <b>Utilizes the Company’s AlloSCOPE™ 5D Manufacturing Process, Featuring Seamless, Bioreactor-based Expansion and Differentiation</b> </li> <li> <b>Proprietary “Thaw and Inject (TAI)” Formulation Offers an Immediate-use Cryopreserved Product Profile to Facilitate Long-Term Storage</b> </li> <li> <b>Current Purity, Scale and Thaw-and-Inject Formulation Support a Superior Product Profile to Cadaver-Sourced Cells</b> </li> </ul> <p> CARLSBAD, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54568450&amp;newsitemid=20260713449564&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=509e3b06b1595c04db5374140f8a1d93" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, “off http://www.streetinsider.com/Business+Wire/Lineage+Provides+Update+on+COR1+Cell+Therapy+Program+for+Corneal+Endothelial+Disease/26760042.html Mon, 13 Jul 2026 08:00:00 -0400 A.36512754 A.40151759 LCTX LCTX O.00050368 O.01207978 O.02770996 http://www.streetinsider.com/Business+Wire/Lineage+Provides+Update+on+COR1+Cell+Therapy+Program+for+Corneal+Endothelial+Disease/26760042.html <p class="bwalignc"> <b>Company Will Host Conference Call Today at 4:30 PM ET / 1:30 PM PT</b> </p><ul class="bwlistdisc"> <li> <b>COR1 Aims to Provide an “Off the Shelf” Supply of Allogeneic CEnCs for Patients Suffering from Corneal Endothelial Disease</b> </li> <li> <b>Utilizes the Company’s AlloSCOPE™ 5D Manufacturing Process, Featuring Seamless, Bioreactor-based Expansion and Differentiation</b> </li> <li> <b>Proprietary “Thaw and Inject (TAI)” Formulation Offers an Immediate-use Cryopreserved Product Profile to Facilitate Long-Term Storage</b> </li> <li> <b>Current Purity, Scale and Thaw-and-Inject Formulation Support a Superior Product Profile to Cadaver-Sourced Cells</b> </li> </ul> <p> CARLSBAD, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54568450&amp;newsitemid=20260713449564&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=509e3b06b1595c04db5374140f8a1d93" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, “off http://www.streetinsider.com/Business+Wire/Lineage+Provides+Update+on+COR1+Cell+Therapy+Program+for+Corneal+Endothelial+Disease/26760042.html Mon, 13 Jul 2026 08:00:00 -0400 A.36512754 A.40151759 LCTX LCTX O.00050368 O.01207978 O.02770996 http://www.streetinsider.com/Business+Wire/Lineage+Provides+Update+on+COR1+Cell+Therapy+Program+for+Corneal+Endothelial+Disease/26760042.html <p class="bwalignc"> <b>Company Will Host Conference Call Today at 4:30 PM ET / 1:30 PM PT</b> </p><ul class="bwlistdisc"> <li> <b>COR1 Aims to Provide an “Off the Shelf” Supply of Allogeneic CEnCs for Patients Suffering from Corneal Endothelial Disease</b> </li> <li> <b>Utilizes the Company’s AlloSCOPE™ 5D Manufacturing Process, Featuring Seamless, Bioreactor-based Expansion and Differentiation</b> </li> <li> <b>Proprietary “Thaw and Inject (TAI)” Formulation Offers an Immediate-use Cryopreserved Product Profile to Facilitate Long-Term Storage</b> </li> <li> <b>Current Purity, Scale and Thaw-and-Inject Formulation Support a Superior Product Profile to Cadaver-Sourced Cells</b> </li> </ul> <p> CARLSBAD, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54568450&amp;newsitemid=20260713449564&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=509e3b06b1595c04db5374140f8a1d93" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, “off http://www.streetinsider.com/Business+Wire/Lineage+Provides+Update+on+COR1+Cell+Therapy+Program+for+Corneal+Endothelial+Disease/26760042.html Mon, 13 Jul 2026 08:00:00 -0400 A.36512754 A.40151759 LCTX LCTX O.00050368 O.01207978 O.02770996 http://www.streetinsider.com/Business+Wire/Lineage+Provides+Update+on+COR1+Cell+Therapy+Program+for+Corneal+Endothelial+Disease/26760042.html <p class="bwalignc"> <b>Company Will Host Conference Call Today at 4:30 PM ET / 1:30 PM PT</b> </p><ul class="bwlistdisc"> <li> <b>COR1 Aims to Provide an “Off the Shelf” Supply of Allogeneic CEnCs for Patients Suffering from Corneal Endothelial Disease</b> </li> <li> <b>Utilizes the Company’s AlloSCOPE™ 5D Manufacturing Process, Featuring Seamless, Bioreactor-based Expansion and Differentiation</b> </li> <li> <b>Proprietary “Thaw and Inject (TAI)” Formulation Offers an Immediate-use Cryopreserved Product Profile to Facilitate Long-Term Storage</b> </li> <li> <b>Current Purity, Scale and Thaw-and-Inject Formulation Support a Superior Product Profile to Cadaver-Sourced Cells</b> </li> </ul> <p> CARLSBAD, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54568450&amp;newsitemid=20260713449564&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=509e3b06b1595c04db5374140f8a1d93" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, “off http://www.streetinsider.com/Business+Wire/Lineage+Provides+Update+on+COR1+Cell+Therapy+Program+for+Corneal+Endothelial+Disease/26760042.html Mon, 13 Jul 2026 08:00:00 -0400 A.36512754 A.40151759 LCTX LCTX O.00050368 O.01207978 O.02770996 http://www.streetinsider.com/Business+Wire/Lineage+Provides+Update+on+COR1+Cell+Therapy+Program+for+Corneal+Endothelial+Disease/26760042.html <p class="bwalignc"> <b>Company Will Host Conference Call Today at 4:30 PM ET / 1:30 PM PT</b> </p><ul class="bwlistdisc"> <li> <b>COR1 Aims to Provide an “Off the Shelf” Supply of Allogeneic CEnCs for Patients Suffering from Corneal Endothelial Disease</b> </li> <li> <b>Utilizes the Company’s AlloSCOPE™ 5D Manufacturing Process, Featuring Seamless, Bioreactor-based Expansion and Differentiation</b> </li> <li> <b>Proprietary “Thaw and Inject (TAI)” Formulation Offers an Immediate-use Cryopreserved Product Profile to Facilitate Long-Term Storage</b> </li> <li> <b>Current Purity, Scale and Thaw-and-Inject Formulation Support a Superior Product Profile to Cadaver-Sourced Cells</b> </li> </ul> <p> CARLSBAD, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54568450&amp;newsitemid=20260713449564&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=509e3b06b1595c04db5374140f8a1d93" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, “off http://www.streetinsider.com/Business+Wire/Lineage+Provides+Update+on+COR1+Cell+Therapy+Program+for+Corneal+Endothelial+Disease/26760042.html Mon, 13 Jul 2026 08:00:00 -0400 A.36512754 A.40151759 LCTX LCTX O.00050368 O.01207978 O.02770996 http://www.streetinsider.com/Business+Wire/Lineage+Provides+Update+on+COR1+Cell+Therapy+Program+for+Corneal+Endothelial+Disease/26760042.html <p class="bwalignc"> <b>Company Will Host Conference Call Today at 4:30 PM ET / 1:30 PM PT</b> </p><ul class="bwlistdisc"> <li> <b>COR1 Aims to Provide an “Off the Shelf” Supply of Allogeneic CEnCs for Patients Suffering from Corneal Endothelial Disease</b> </li> <li> <b>Utilizes the Company’s AlloSCOPE™ 5D Manufacturing Process, Featuring Seamless, Bioreactor-based Expansion and Differentiation</b> </li> <li> <b>Proprietary “Thaw and Inject (TAI)” Formulation Offers an Immediate-use Cryopreserved Product Profile to Facilitate Long-Term Storage</b> </li> <li> <b>Current Purity, Scale and Thaw-and-Inject Formulation Support a Superior Product Profile to Cadaver-Sourced Cells</b> </li> </ul> <p> CARLSBAD, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54568450&amp;newsitemid=20260713449564&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=509e3b06b1595c04db5374140f8a1d93" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, “off http://www.streetinsider.com/Business+Wire/Lineage+Provides+Update+on+COR1+Cell+Therapy+Program+for+Corneal+Endothelial+Disease/26760042.html Mon, 13 Jul 2026 08:00:00 -0400 A.36512754 A.40151759 LCTX LCTX O.00050368 O.01207978 O.02770996 http://www.streetinsider.com/Press+Releases/Lineage+Cell+Therapeutics+to+Present+at+B.+Riley+Securities+2026+Mind%2C+Muscle+%26amp%3B+Vision+Healthcare+Summit/26732940.html <p> CARLSBAD, Calif.--(BUSINESS WIRE)--</p> <p class="bwalignl"> <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54564502&amp;newsitemid=20260706121432&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=92c7c397c83bb15e4adb49fe374f34cd" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” allogeneic cell therapies for serious medical conditions, today announced that Brian M. Culley, Lineage’s Chief Executive Officer, will be presenting at the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.brileysecurities.com%2Fblog%2Fb.riley-securities-to-host-mind-muscle-vision-healthcare-summit-on-july-16-2026&amp;esheet=54564502&amp;newsitemid=20260706121432&amp;lan=en-US&amp;anchor=B.+Riley+Securities+2026+Mind%2C+Muscle+%26amp%3B+Vision+Healthcare+Summit&amp;index=2&amp;md5=cec769c53ac12caf0de1f806a11d40e8" shape="rect">B. Riley Securities 2026 Mind, Muscle &amp; Vision Healthcare Summit</a>, in a fireside chat hosted by Mayank Mamtani, Senior Managing Director, Group Head of Healthcare Research and Senior Biotechnology Analyst. The B. Riley Securities 2026 Mind, Muscle &amp; Vision Healthcare Summit will take place on July http://www.streetinsider.com/Press+Releases/Lineage+Cell+Therapeutics+to+Present+at+B.+Riley+Securities+2026+Mind%2C+Muscle+%26amp%3B+Vision+Healthcare+Summit/26732940.html Mon, 06 Jul 2026 08:00:00 -0400 A.50202486 LCTX LCTX O.02770996 O.53171475 http://www.streetinsider.com/Press+Releases/Lineage+Cell+Therapeutics+to+Present+at+B.+Riley+Securities+2026+Mind%2C+Muscle+%26amp%3B+Vision+Healthcare+Summit/26732940.html <p> CARLSBAD, Calif.--(BUSINESS WIRE)--</p> <p class="bwalignl"> <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54564502&amp;newsitemid=20260706121432&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=92c7c397c83bb15e4adb49fe374f34cd" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” allogeneic cell therapies for serious medical conditions, today announced that Brian M. Culley, Lineage’s Chief Executive Officer, will be presenting at the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.brileysecurities.com%2Fblog%2Fb.riley-securities-to-host-mind-muscle-vision-healthcare-summit-on-july-16-2026&amp;esheet=54564502&amp;newsitemid=20260706121432&amp;lan=en-US&amp;anchor=B.+Riley+Securities+2026+Mind%2C+Muscle+%26amp%3B+Vision+Healthcare+Summit&amp;index=2&amp;md5=cec769c53ac12caf0de1f806a11d40e8" shape="rect">B. Riley Securities 2026 Mind, Muscle &amp; Vision Healthcare Summit</a>, in a fireside chat hosted by Mayank Mamtani, Senior Managing Director, Group Head of Healthcare Research and Senior Biotechnology Analyst. The B. Riley Securities 2026 Mind, Muscle &amp; Vision Healthcare Summit will take place on July http://www.streetinsider.com/Press+Releases/Lineage+Cell+Therapeutics+to+Present+at+B.+Riley+Securities+2026+Mind%2C+Muscle+%26amp%3B+Vision+Healthcare+Summit/26732940.html Mon, 06 Jul 2026 08:00:00 -0400 A.50202486 LCTX LCTX O.02770996 O.53171475 http://www.streetinsider.com/Press+Releases/Lineage+Cell+Therapeutics+to+Present+at+B.+Riley+Securities+2026+Mind%2C+Muscle+%26amp%3B+Vision+Healthcare+Summit/26732940.html <p> CARLSBAD, Calif.--(BUSINESS WIRE)--</p> <p class="bwalignl"> <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54564502&amp;newsitemid=20260706121432&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=92c7c397c83bb15e4adb49fe374f34cd" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” allogeneic cell therapies for serious medical conditions, today announced that Brian M. Culley, Lineage’s Chief Executive Officer, will be presenting at the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.brileysecurities.com%2Fblog%2Fb.riley-securities-to-host-mind-muscle-vision-healthcare-summit-on-july-16-2026&amp;esheet=54564502&amp;newsitemid=20260706121432&amp;lan=en-US&amp;anchor=B.+Riley+Securities+2026+Mind%2C+Muscle+%26amp%3B+Vision+Healthcare+Summit&amp;index=2&amp;md5=cec769c53ac12caf0de1f806a11d40e8" shape="rect">B. Riley Securities 2026 Mind, Muscle &amp; Vision Healthcare Summit</a>, in a fireside chat hosted by Mayank Mamtani, Senior Managing Director, Group Head of Healthcare Research and Senior Biotechnology Analyst. The B. Riley Securities 2026 Mind, Muscle &amp; Vision Healthcare Summit will take place on July http://www.streetinsider.com/Press+Releases/Lineage+Cell+Therapeutics+to+Present+at+B.+Riley+Securities+2026+Mind%2C+Muscle+%26amp%3B+Vision+Healthcare+Summit/26732940.html Mon, 06 Jul 2026 08:00:00 -0400 A.50202486 LCTX LCTX O.02770996 O.53171475 http://www.streetinsider.com/Press+Releases/Lineage+Cell+Therapeutics+to+Present+at+B.+Riley+Securities+2026+Mind%2C+Muscle+%26amp%3B+Vision+Healthcare+Summit/26732940.html <p> CARLSBAD, Calif.--(BUSINESS WIRE)--</p> <p class="bwalignl"> <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54564502&amp;newsitemid=20260706121432&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=92c7c397c83bb15e4adb49fe374f34cd" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” allogeneic cell therapies for serious medical conditions, today announced that Brian M. Culley, Lineage’s Chief Executive Officer, will be presenting at the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.brileysecurities.com%2Fblog%2Fb.riley-securities-to-host-mind-muscle-vision-healthcare-summit-on-july-16-2026&amp;esheet=54564502&amp;newsitemid=20260706121432&amp;lan=en-US&amp;anchor=B.+Riley+Securities+2026+Mind%2C+Muscle+%26amp%3B+Vision+Healthcare+Summit&amp;index=2&amp;md5=cec769c53ac12caf0de1f806a11d40e8" shape="rect">B. Riley Securities 2026 Mind, Muscle &amp; Vision Healthcare Summit</a>, in a fireside chat hosted by Mayank Mamtani, Senior Managing Director, Group Head of Healthcare Research and Senior Biotechnology Analyst. The B. Riley Securities 2026 Mind, Muscle &amp; Vision Healthcare Summit will take place on July http://www.streetinsider.com/Press+Releases/Lineage+Cell+Therapeutics+to+Present+at+B.+Riley+Securities+2026+Mind%2C+Muscle+%26amp%3B+Vision+Healthcare+Summit/26732940.html Mon, 06 Jul 2026 08:00:00 -0400 A.50202486 LCTX LCTX O.02770996 O.53171475 http://www.streetinsider.com/Press+Releases/Lineage+Cell+Therapeutics+to+Present+at+B.+Riley+Securities+2026+Mind%2C+Muscle+%26amp%3B+Vision+Healthcare+Summit/26732940.html <p> CARLSBAD, Calif.--(BUSINESS WIRE)--</p> <p class="bwalignl"> <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54564502&amp;newsitemid=20260706121432&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=92c7c397c83bb15e4adb49fe374f34cd" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” allogeneic cell therapies for serious medical conditions, today announced that Brian M. Culley, Lineage’s Chief Executive Officer, will be presenting at the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.brileysecurities.com%2Fblog%2Fb.riley-securities-to-host-mind-muscle-vision-healthcare-summit-on-july-16-2026&amp;esheet=54564502&amp;newsitemid=20260706121432&amp;lan=en-US&amp;anchor=B.+Riley+Securities+2026+Mind%2C+Muscle+%26amp%3B+Vision+Healthcare+Summit&amp;index=2&amp;md5=cec769c53ac12caf0de1f806a11d40e8" shape="rect">B. Riley Securities 2026 Mind, Muscle &amp; Vision Healthcare Summit</a>, in a fireside chat hosted by Mayank Mamtani, Senior Managing Director, Group Head of Healthcare Research and Senior Biotechnology Analyst. The B. Riley Securities 2026 Mind, Muscle &amp; Vision Healthcare Summit will take place on July http://www.streetinsider.com/Press+Releases/Lineage+Cell+Therapeutics+to+Present+at+B.+Riley+Securities+2026+Mind%2C+Muscle+%26amp%3B+Vision+Healthcare+Summit/26732940.html Mon, 06 Jul 2026 08:00:00 -0400 A.50202486 LCTX LCTX O.02770996 O.53171475 http://www.streetinsider.com/Business+Wire/Lineage+Cell+Therapeutics+to+Present+at+B.+Riley+Securities+2026+Mind%2C+Muscle+%26amp%3B+Vision+Healthcare+Summit/26732940.html <p> CARLSBAD, Calif.--(BUSINESS WIRE)--</p> <p class="bwalignl"> <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54564502&amp;newsitemid=20260706121432&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=92c7c397c83bb15e4adb49fe374f34cd" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” allogeneic cell therapies for serious medical conditions, today announced that Brian M. Culley, Lineage’s Chief Executive Officer, will be presenting at the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.brileysecurities.com%2Fblog%2Fb.riley-securities-to-host-mind-muscle-vision-healthcare-summit-on-july-16-2026&amp;esheet=54564502&amp;newsitemid=20260706121432&amp;lan=en-US&amp;anchor=B.+Riley+Securities+2026+Mind%2C+Muscle+%26amp%3B+Vision+Healthcare+Summit&amp;index=2&amp;md5=cec769c53ac12caf0de1f806a11d40e8" shape="rect">B. Riley Securities 2026 Mind, Muscle &amp; Vision Healthcare Summit</a>, in a fireside chat hosted by Mayank Mamtani, Senior Managing Director, Group Head of Healthcare Research and Senior Biotechnology Analyst. The B. Riley Securities 2026 Mind, Muscle &amp; Vision Healthcare Summit will take place on July http://www.streetinsider.com/Business+Wire/Lineage+Cell+Therapeutics+to+Present+at+B.+Riley+Securities+2026+Mind%2C+Muscle+%26amp%3B+Vision+Healthcare+Summit/26732940.html Mon, 06 Jul 2026 08:00:00 -0400 A.50202486 LCTX LCTX O.02770996 O.53171475 http://www.streetinsider.com/Business+Wire/Lineage+Cell+Therapeutics+to+Present+at+B.+Riley+Securities+2026+Mind%2C+Muscle+%26amp%3B+Vision+Healthcare+Summit/26732940.html <p> CARLSBAD, Calif.--(BUSINESS WIRE)--</p> <p class="bwalignl"> <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54564502&amp;newsitemid=20260706121432&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=92c7c397c83bb15e4adb49fe374f34cd" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” allogeneic cell therapies for serious medical conditions, today announced that Brian M. Culley, Lineage’s Chief Executive Officer, will be presenting at the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.brileysecurities.com%2Fblog%2Fb.riley-securities-to-host-mind-muscle-vision-healthcare-summit-on-july-16-2026&amp;esheet=54564502&amp;newsitemid=20260706121432&amp;lan=en-US&amp;anchor=B.+Riley+Securities+2026+Mind%2C+Muscle+%26amp%3B+Vision+Healthcare+Summit&amp;index=2&amp;md5=cec769c53ac12caf0de1f806a11d40e8" shape="rect">B. Riley Securities 2026 Mind, Muscle &amp; Vision Healthcare Summit</a>, in a fireside chat hosted by Mayank Mamtani, Senior Managing Director, Group Head of Healthcare Research and Senior Biotechnology Analyst. The B. Riley Securities 2026 Mind, Muscle &amp; Vision Healthcare Summit will take place on July http://www.streetinsider.com/Business+Wire/Lineage+Cell+Therapeutics+to+Present+at+B.+Riley+Securities+2026+Mind%2C+Muscle+%26amp%3B+Vision+Healthcare+Summit/26732940.html Mon, 06 Jul 2026 08:00:00 -0400 A.50202486 LCTX LCTX O.02770996 O.53171475 http://www.streetinsider.com/Business+Wire/Lineage+Cell+Therapeutics+to+Present+at+B.+Riley+Securities+2026+Mind%2C+Muscle+%26amp%3B+Vision+Healthcare+Summit/26732940.html <p> CARLSBAD, Calif.--(BUSINESS WIRE)--</p> <p class="bwalignl"> <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54564502&amp;newsitemid=20260706121432&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=92c7c397c83bb15e4adb49fe374f34cd" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” allogeneic cell therapies for serious medical conditions, today announced that Brian M. Culley, Lineage’s Chief Executive Officer, will be presenting at the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.brileysecurities.com%2Fblog%2Fb.riley-securities-to-host-mind-muscle-vision-healthcare-summit-on-july-16-2026&amp;esheet=54564502&amp;newsitemid=20260706121432&amp;lan=en-US&amp;anchor=B.+Riley+Securities+2026+Mind%2C+Muscle+%26amp%3B+Vision+Healthcare+Summit&amp;index=2&amp;md5=cec769c53ac12caf0de1f806a11d40e8" shape="rect">B. Riley Securities 2026 Mind, Muscle &amp; Vision Healthcare Summit</a>, in a fireside chat hosted by Mayank Mamtani, Senior Managing Director, Group Head of Healthcare Research and Senior Biotechnology Analyst. The B. Riley Securities 2026 Mind, Muscle &amp; Vision Healthcare Summit will take place on July http://www.streetinsider.com/Business+Wire/Lineage+Cell+Therapeutics+to+Present+at+B.+Riley+Securities+2026+Mind%2C+Muscle+%26amp%3B+Vision+Healthcare+Summit/26732940.html Mon, 06 Jul 2026 08:00:00 -0400 A.50202486 LCTX LCTX O.02770996 O.53171475 http://www.streetinsider.com/Business+Wire/Lineage+Cell+Therapeutics+to+Present+at+B.+Riley+Securities+2026+Mind%2C+Muscle+%26amp%3B+Vision+Healthcare+Summit/26732940.html <p> CARLSBAD, Calif.--(BUSINESS WIRE)--</p> <p class="bwalignl"> <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54564502&amp;newsitemid=20260706121432&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=92c7c397c83bb15e4adb49fe374f34cd" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” allogeneic cell therapies for serious medical conditions, today announced that Brian M. Culley, Lineage’s Chief Executive Officer, will be presenting at the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.brileysecurities.com%2Fblog%2Fb.riley-securities-to-host-mind-muscle-vision-healthcare-summit-on-july-16-2026&amp;esheet=54564502&amp;newsitemid=20260706121432&amp;lan=en-US&amp;anchor=B.+Riley+Securities+2026+Mind%2C+Muscle+%26amp%3B+Vision+Healthcare+Summit&amp;index=2&amp;md5=cec769c53ac12caf0de1f806a11d40e8" shape="rect">B. Riley Securities 2026 Mind, Muscle &amp; Vision Healthcare Summit</a>, in a fireside chat hosted by Mayank Mamtani, Senior Managing Director, Group Head of Healthcare Research and Senior Biotechnology Analyst. The B. Riley Securities 2026 Mind, Muscle &amp; Vision Healthcare Summit will take place on July http://www.streetinsider.com/Business+Wire/Lineage+Cell+Therapeutics+to+Present+at+B.+Riley+Securities+2026+Mind%2C+Muscle+%26amp%3B+Vision+Healthcare+Summit/26732940.html Mon, 06 Jul 2026 08:00:00 -0400 A.50202486 LCTX LCTX O.02770996 O.53171475 http://www.streetinsider.com/Business+Wire/Lineage+Cell+Therapeutics+to+Present+at+B.+Riley+Securities+2026+Mind%2C+Muscle+%26amp%3B+Vision+Healthcare+Summit/26732940.html <p> CARLSBAD, Calif.--(BUSINESS WIRE)--</p> <p class="bwalignl"> <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54564502&amp;newsitemid=20260706121432&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=92c7c397c83bb15e4adb49fe374f34cd" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” allogeneic cell therapies for serious medical conditions, today announced that Brian M. Culley, Lineage’s Chief Executive Officer, will be presenting at the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.brileysecurities.com%2Fblog%2Fb.riley-securities-to-host-mind-muscle-vision-healthcare-summit-on-july-16-2026&amp;esheet=54564502&amp;newsitemid=20260706121432&amp;lan=en-US&amp;anchor=B.+Riley+Securities+2026+Mind%2C+Muscle+%26amp%3B+Vision+Healthcare+Summit&amp;index=2&amp;md5=cec769c53ac12caf0de1f806a11d40e8" shape="rect">B. Riley Securities 2026 Mind, Muscle &amp; Vision Healthcare Summit</a>, in a fireside chat hosted by Mayank Mamtani, Senior Managing Director, Group Head of Healthcare Research and Senior Biotechnology Analyst. The B. Riley Securities 2026 Mind, Muscle &amp; Vision Healthcare Summit will take place on July http://www.streetinsider.com/Business+Wire/Lineage+Cell+Therapeutics+to+Present+at+B.+Riley+Securities+2026+Mind%2C+Muscle+%26amp%3B+Vision+Healthcare+Summit/26732940.html Mon, 06 Jul 2026 08:00:00 -0400 A.50202486 LCTX LCTX O.02770996 O.53171475